loading page

Identification of RCC1- LCK as a novel fusion gene in pediatric erythroid sarcoma
  • +9
  • Satoru Oya,
  • Shinya Osone,
  • Masanori Yoshida,
  • Sota Nishimoto,
  • Yoshihiro Taura,
  • Hideki Yoshida,
  • Mitsuru Miyachi,
  • Tohru Inaba,
  • Eiichi Konishi,
  • Motohiro Kato,
  • Toshihiko Imamura,
  • Tomoko Iehara
Satoru Oya
Kyoto Prefectural University of Medicine School of Medicine Graduate School of Medical Science

Corresponding Author:[email protected]

Author Profile
Shinya Osone
Kyoto Prefectural University of Medicine, Graduate School of Medical Science
Author Profile
Masanori Yoshida
National Center for Child Health and Development
Author Profile
Sota Nishimoto
Kyoto Prefectural University of Medicine
Author Profile
Yoshihiro Taura
Kyoto Prefectural University of Medicine School of Medicine Graduate School of Medical Science
Author Profile
Hideki Yoshida
Kyoto Prefectural University of Medicine
Author Profile
Mitsuru Miyachi
Kyoto Prefectural University of Medicine
Author Profile
Tohru Inaba
Kyoto Prefectural University of Medicine
Author Profile
Eiichi Konishi
Kyoto Prefectural University of Medicine
Author Profile
Motohiro Kato
The University of Tokyo
Author Profile
Toshihiko Imamura
Kyoto Prefectural University of Medicine
Author Profile
Tomoko Iehara
Kyoto Prefectural University of Medicine
Author Profile

Abstract

Erythroid sarcoma is very rare form of pure erythroid leukemia with undetermined biological features. Here, we present an infant with a multifocal erythroid sarcoma, diagnosed because the tumor cells were positive for glycophorin A. After acute myeloid leukemia-oriented chemotherapy and surgical resection followed by cord blood transplantation, he has successfully maintained complete remission without any late effects. Total transcriptome analysis of the tumor identified a novel fusion gene, RCC1-LCK, and high LCK expression levels, suggesting that LCK overexpression was involved in leukemogenesis in this case.
10 Apr 2022Submitted to Pediatric Blood & Cancer
10 Apr 2022Submission Checks Completed
10 Apr 2022Assigned to Editor
15 Apr 2022Reviewer(s) Assigned
03 May 2022Review(s) Completed, Editorial Evaluation Pending
05 May 2022Editorial Decision: Revise Major
27 May 2022Submission Checks Completed
27 May 2022Assigned to Editor
27 May 20221st Revision Received
30 May 2022Review(s) Completed, Editorial Evaluation Pending
30 May 2022Editorial Decision: Accept
Sep 2022Published in Pediatric Blood & Cancer volume 69 issue 9. 10.1002/pbc.29848